RedHill Biopharma (RDHL) Goodwill & Intangibles (2011 - 2025)

RedHill Biopharma (RDHL) has reported Goodwill & Intangibles for 15 consecutive years, with $5.3 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Goodwill & Intangibles fell 4.62% year-over-year to $5.3 million in Q4 2025; TTM through Dec 2025 was $5.3 million, a 4.62% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, down 4.62% from the prior year.
• Goodwill & Intangibles was $5.3 million for Q4 2025 at RedHill Biopharma, down from $5.5 million in the prior quarter.
• Over five years, Goodwill & Intangibles peaked at $86.1 million in Q1 2021 and troughed at -$59.5 million in Q2 2023.
• A 5-year average of $33.6 million and a median of $65.6 million in 2022 frame the typical range for Goodwill & Intangibles.
• Across the five-year window, Goodwill & Intangibles surged 442.88% in 2021 and sank 190.67% in 2023, its largest moves.
• Over 5 years, Goodwill & Intangibles stood at $71.6 million in 2021, then declined by 8.4% to $65.6 million in 2022, then slumped by 190.67% to -$59.5 million in 2023, then surged by 109.32% to $5.5 million in 2024, then retreated by 4.62% to $5.3 million in 2025.
• The last three Goodwill & Intangibles figures came in at $5.3 million (Q4 2025), $5.5 million (Q2 2025), and $5.5 million (Q4 2024), per Business Quant data.